Infectious disease
Regeneron announced positive initial data from its ongoing Phase III trial of its antibody cocktail, REGEN-COV, as a passive vaccine to prevent COVID-19 in people at high risk of infection from household exposure.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 26, 2021.
British scientists suggested last week that the U.K. variant may be approximately 30% more lethal than the most common strain that came out of China. But they’re not completely sure of this yet.
Moderna announced it has started development on a booster to its COVID-19 vaccine, which the company hopes will work against the recently discovered (and more transmissible) SARS-CoV-2 variant from South Africa.
Pfizer, Moderna, AstraZeneca, and Johnson & Johnson all have trials of their respective vaccines underway in various age-groups.
Industry-leading biotech CSL is leveraging its integrated global portfolio to bring urgently needed therapeutic COVID-19 treatments to patients around the world.
A study from researchers at Monash University in Melbourne has identified two molecules in the gut microbiome that can protect against asthma and may possibly reduce the severity of an asthma attack.
Merck announced that it is going to stop developing its two COVID-19 vaccine candidates, dubbed V590 and V591, after poor responses in Phase I trials.
Americans are still hesitant to be vaccinated against COVID-19, according to just-released research from Invisibly.
Despite the rising number of COVID-19 cases reported across the globe, rates of influenza have virtually flatlined across the Northern Hemisphere, leading many doctors and researchers to wonder how this could be replicated in non-pandemic times.
PRESS RELEASES